David D. Chang - Mar 22, 2023 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Role
President and CEO, Director
Signature
/s/Veer Bhavnagri, Attorney-in-Fact
Stock symbol
ALLO
Transactions as of
Mar 22, 2023
Transactions value $
$0
Form type
4
Date filed
3/24/2023, 08:13 PM
Previous filing
Mar 16, 2023
Next filing
Jan 31, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Award $0 +1.92M +84.8% $0.00 4.19M Mar 22, 2023 Direct F1
holding ALLO Common Stock 1.2M Mar 22, 2023 See footnote F2
holding ALLO Common Stock 856K Mar 22, 2023 See footnote F3
holding ALLO Common Stock 856K Mar 22, 2023 See footnote F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALLO Stock Option (Right to Buy) Award $0 +1.49M $0.00 1.49M Mar 22, 2023 Common Stock 1.49M $5.04 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 1,480,357 of performance RSUs which shall vest as follows: (1) 50% shall vest if the 30-day weighted average stock price is equal to or greater than $18 and (2) 50% shall vest upon the first regulatory approval of a product candidate. Notwithstanding the foregoing (1) any portion that vests upon the stock price threshold shall no longer vest and be terminated after three years from the grant date if such threshold has not been met in such three-year period, and (2) any portion that vests upon product candidate approval shall no longer vest and be terminated after five years from the grant date if such approval has not occurred in such five-year period.
F2 Securities held in the name of the Chang 2006 Family Trust
F3 Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
F4 Securities held in the name of the RTC 2019 Trust dated October 1, 2019.
F5 25% of the shares subject to the stock option shall vest on March 13, 2024, and the remaining shares shall vest in 36 equal monthly installments thereafter.